Simulations Plus is fast tracking its consulting services for businesses working on coronavirus research, the company said in a statement Thursday. The Lancaster drug modeling software company created its StrategiesPlus COVID-19 ACT program to provide specialized expertise to biopharma companies looking to create safe and effective treatments for the virus. Companies involved in the program will be able to use GastroPlus software to investigate which mode of dosing – such as inhalation or oral – is most effective, and compile data to present to regulators for approval. Also, Simulation Plus’ DILIsym product can help companies determine toxicity risk, or if a drug will cause pulmonary or cardiac-related injuries. Viral dynamics models developed by Cognigen, acquired by Simulations Plus in June 2014, help predict how a virus-addled body will react to a drug. “We are adjusting our standard business priorities and schedule to prepare to provide immediate support for pharmaceutical research and development efforts,” Dan O’Connor, director of business development for Simulation Sciences, a division of Simulations Plus, said in a statement. “Our scientists are eager to help teams expedite solutions to address the COVID-19 virus.” Shares of Simulations Plus (SLP) closed Thursday up $1.62, or more than 5 percent, to $32.67 on the Nasdaq.
